Figure 6.

PKC inhibition restores the DLX3cKO epidermal barrier alteration and inflammatory phenotype. (a) Heatmaps of differentially expressed mRNAs in WT or DLX3cKO skin treated with GF109203X or acetone (control) related to the top affected clusters by DAVID functional annotation analysis: epidermal barrier disruption (left), cytokine/chemokine (middle) and antimicrobial peptides (right). Expression values are colored based on their z-score after normalization across treatments. (b) Immunohistochemical staining of GF109203X-treated WT and DLX3cKO transgenic skin with antibodies against CD45. Nuclei were stained with DAPI. Scale bar, 20 μm. Data are presented as mean±S.D. of three different areas from three different mice for each condition. (c) Heatmap of the cytokines released by WT or DLX3cKO keratinocytes after treatment with GF109203X in culture for 24 h. DMSO was used as a control. Cytokine concentration values are colored based on their z-score after normalization across treatments